Opportunities for Swedish Academic Researchers to explore biology and accelerate Drug Discovery and Development through the open innovation platforms
Chemical Biology Consortium Sweden (CBCS), Drug Discovery and Development platform (DDD) at ScilifeLab and Astra Zeneca Open Innovation visit Lund.
Anna-Lena Gustavsson, CBCS, and Per Arvidsson, DDD, will present what the SciLifeLab platforms offers to the academic research community.
David Smith, Thomas Lundbäck and Andy Davis’ presentation “Open innovation partnerships at Astra Zeneca: Breaking down barriers to create value through collaboration” will describe Astra Zeneca’ Open Innovation platform. Through case study examples they will describe how Open Innovation works at AstraZeneca, and the breadth of the opportunities available to work together.
Following the presentations and discussions we are happy to meet with individual research groups.
Please register by sending an e-mail to annie [dot] chandy [at] innovation [dot] lu [dot] se no later than 5 October.
Coffee & Sandwich will be served
CBCS (www.cbcs.se) provides expertise and instrumentation for assay development and small molecule screening with the goal to explore disease biology and ”drugability” of targets and biological pathways using chemical tool compounds.
Drug Discovery & Development platform (DDD) offers integrated drug discovery efforts to the academic research community. DDD offers industry standard infrastructure, expertise, and strategic support to help progress projects towards a pre-clinical proof-of-concept. The drug leads can be either a small molecule drug or a human antibody therapeutic.
AstraZeneca Open Innovation makes available more than 20 clinical ready compounds for novel clinical and translational science. The high throughput screening small molecule collection contains over 250,000 compounds and provides an excellent basis for diversity-based hit finding, with follow-up neighbor searches reaching back into their 2.2 million compound library. A fragment library is also available, and even a highly annotated phenotypic screening collection for new target identification.